Clinical trial examines use of human immune system to fight aggressive lung cancer

December 19, 2013

Researchers at the Cincinnati Cancer Center (CCC) and the UC Cancer Institute are conducting a clinical trial examining a method to stimulate the human immune system to destroy or block the growth of lung cancer cells.

This trial could lead to a new therapy, which uses natural biological processes within the body, to eliminate cancer growth and enhance the lives of patients with recurrent lung cancer.

John Morris, MD, clinical co-leader of the Molecular Therapeutics and Diagnosis Program for the CCC, co-leader of the UC Cancer Institute's Comprehensive Lung Cancer Program, professor in the division of hematology oncology at the UC College of Medicine and UC Health medical oncologist, is the co-principal investigator on the trial along with colleagues at the Alvin J Siteman Cancer Center at Washington University in St. Louis.

"Non-small cell lung cancer, the most common type of lung cancer, remains the leading cause of cancer death in men and women in the United States," Morris says. "Despite advances in the treatment of non-small cell lung cancer in the last decade, outcomes remain poor. Benefits from standard chemotherapy have reached a plateau, and further progress will depend upon identifying new treatments that specifically target tumor cells.

"Harnessing the human to target lung cancer could result in the development of effective treatment options against lung cancer and potentially enhance the effect of chemotherapy."

Morris says lung produce a number of abnormal proteins or abnormal amounts of certain proteins found in normal lung cells, and in some cancers, the abnormal protein expression may lead to an against the cancer cells in a similar way that the immune system responds to an infection.

"In progressive lung cancer, however, the immune system fails to identify or respond to these abnormalities, and the cancer cells are not attacked or destroyed for reasons not yet fully understood," he continues. "This clinical trial will examine a method to stimulate the human immune system to recognize the abnormal components found in lung cancer cells and hopefully to stimulate an immune response that will stop the growth of cancer, helping the immune system of patients with lung cancer to identify and target the cancerous tissue."

Morris says the idea behind this immunotherapy is similar to the reason that patients who have received a transplanted organ or tissue from another species, like a mouse or pig, will rapidly reject the foreign tissue.

In the study, researchers put an animal gene into cultured human lung cancer cells, which is thought to stimulate a strong immune response in humans.

"These cancer cells are irradiated to prevent any growth and are then injected into patients with lung cancer, which will then stimulate the patient's immune system to kill the injected immunotherapy cells as well as the patient's own cancer cells as well."

In the study, the immunotherapy is being compared to a Food and Drug Administration-approved second-line chemotherapy drug, docetaxel, to see if the results of the immunotherapy are the same or better.

"As part of the process of destroying the immunotherapy cells, we believe the patient's immune system will be stimulated to identify as many differences between these cancer cells and normal human cells to encourage immune response against the cancerous cells based on shared abnormalities of lung cancer immunotherapy cells and the patient's ," Morris says.

Patients may be given up to 16 doses of the immunotherapy and will be monitored until any progression of their cancer is observed.

"We hope to test these treatments in patients with lung cancer who have progressed after initial chemotherapy to show that treatment of immunotherapy results in improved tumor stabilization or response and could potentially improve the patient's overall outcomes and survival," Morris says. "This could provide more options for who are in the later stages of ."

Explore further: Stem cell finding could advance immunotherapy for lung cancer

Related Stories

Stem cell finding could advance immunotherapy for lung cancer

November 13, 2012
A University of Cincinnati (UC) Cancer Institute lung cancer research team reports that lung cancer stem cells can be isolated—and then grown—in a preclinical model, offering a new avenue for investigating immunotherapy ...

Experimental drug shows encouraging results in treating most common form of lung cancer

November 1, 2013
An experimental cancer drug that has shown promise in the treatment of melanoma has also shown early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death among ...

Some immune cells appear to aid cancer cell growth, study finds

September 5, 2013
The immune system is normally known for protecting the body from illness. But a subset of immune cells appear to be doing more harm than good.

Blocking antioxidants in cancer cells reduces tumor growth in mice

December 2, 2013
Many cancers have adapted to cope with high levels of immune system-produced free radicals, also referred to as reactive oxygen species, by overproducing antioxidant proteins. One of these proteins, superoxide dismutase 1 ...

Experimental drugs for breast cancer could treat lung cancer too

August 13, 2013
Cancer Research UK -funded scientists have discovered that experimental drugs first developed for breast and ovarian cancer could be used to treat the most common type of lung cancer, reveals research published in Oncogene ...

Promising drug prevents cancer cells from shutting down immune system

June 4, 2013
(Medical Xpress)—An investigational drug that targets the immune system's ability to fight cancer is showing promising results in Yale Cancer Center (YCC) patients with a variety of advanced or metastatic forms of the disease. ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.